A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Schwartz, Jill L ^a   Rountree, Wes ^b,h   Kashuba, Angela D M ^c   Brache, Vivian ^d   Creinin, Mitchell D ^e,i   Poindexter, Alfred ^f   Kearney, Brian P ^g  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b FAMILY HEALTH INTERNATIONAL   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d PROFAMILIA   (Dominican Republic)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f Advances in Health Inc   (United States)

^g GILEAD SCIENCES   (United States)

^h DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TENOFOVIR; ADENINE; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ADVERSE OUTCOME; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BACKACHE; BREAST DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; DRUG FATALITY; DRUG TISSUE LEVEL; DYSMENORRHEA; DYSURIA; FEMALE; GASTROINTESTINAL DISEASE; GEL; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; MAXIMUM PLASMA CONCENTRATION; MENORRHAGIA; MORNING DOSAGE; MULTICENTER STUDY; MUSCLE SPASM; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; NORMAL HUMAN; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN ABSCESS; TONSILLITIS; TOOTH PAIN; TREATMENT DURATION; VAGINA BLEEDING; VAGINA PAIN; VAGINAL DISCOMFORT; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; TOPICAL DRUG ADMINISTRATION; VAGINA;

ADENINE; ADMINISTRATION, TOPICAL; ADULT; FEMALE; GELS; HUMANS; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; VAGINA;

EID: 80054786208     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025974     Document Type: Article

References (20)

1. UNAIDS (2010) Report on the global HIV/AIDS epidemic 2010. Available: http://www.unaids.org/globalreport/. Accessed 2011 Sept 16.
2. Robbins BL, Srinivas RV, Kim C, Bischofberger N, Fridland A, (1998) Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob Agents Chemother 42: 612-617.
3. Rohan LC, Moncla BJ, Kunjara Na Ayudhya RP, Cost M, Huang Y, et al. (2010) In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS ONE 5: e9310.
4. Parikh UM, Dobard C, Sharma S, Cong M, Jia H, et al. (2009) Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J Virol 83: 10358-10365.
5. Mayer KH, Maslankowski LA, Gai F, El-Sadr WM, Justman J, et al. (2006) Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS 20: 543-551.
6. Schwartz JL, Poindexter A, Wheeless A, Mauck CK, Callahan MM, (2009) Safety evaluation of 1% tenofovir gel in healthy men. Int J STD AIDS 20: 384-386.
7. Hillier S, (2008) HPTN 059. Microbicides 2008, February 24-27, New Delhi, India.
8. Karim QA, Karim SSA, Frohlich JA, Grobler AC, Baxter C, et al. (2010) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329: 1168-1174.
9. Chapman EH, Kurec AS, Davey FR, (1981) Cell volumes of normal and malignant mononuclear cells. J Clin Pathol 34: 1083-1090.
10. Hawkins T, Veikley WAC, St Claire RL, Guyer B, Clark N, et al. (2005) Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J Acquir Immune Defic Syndr 39: 406-411.
11. St Claire RL III, (2000) Positive ion electrospray ionization tandem mass spectrometry coupled to ion-pairing high-performance liquid chromatography with a phosphate buffer for the quantitative analysis of intracellular nucleotides. Rapid Commun Mass Spectrom 14: 1625-1634.
12. Balzarini J, Holy A, Jindrich J, Naesens L, Snoeck R, et al. (1993) Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrob Agents Chemother 37: 332-338.
13. Wainberg MA, Miller MD, Quan Y, Salomon H, Mulato AS, et al. (1999) In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir Ther 4: 87-94.
14. Borroto-Esoda K, Vela JE, Myrick F, Ray AS, Miller MD, (2006) In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine. Antivir Ther 11: 377-384.
15. Thurman AR, Doncel GF, (2011) Innate immunity and inflammatory response to Trichomonas vaginalis and bacterial vaginosis: relationship to HIV acquisition. American Journal of Reproductive Immunology 65: 89-98.
16. Hoetelmans RMW, Marien K, De Pauw M, Hill A, Peeters M, et al. (2007) Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers. Br J Clin Pharmacol 64: 655-661.
17. Brenner BG, Coutsinos D, (2009) The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications. HIV Ther 3: 583-594.
18. Karim S, Kashuba A, Werner L, Karim Q, (2011) Drug concentrations after topical and antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet 378: 279-281.
19. Parikh UM, Koontz DL, Chu CK, Schinazi RF, Mellors JW, (2005) In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase. Antimicrob Agents Chemother 49: 1139-1144.
20. Dumond JB, Yeh RF, Patterson KB, Corbett AH, Jung BH, et al. (2007) Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS 21: 1899-1907.